Full Title
Phase II Study of Pembrolizumab and Ablative Radiotherapy with or without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune ResponsesPurpose
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
Radiation therapy alone or with olaparib may enhance the ability of the immune system to recognize and destroy TNBC cells, especially when combined with pembrolizumab. The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for women with advanced TNBC. Patients will be randomly assigned to receive radiation therapy and pembrolizumab with or without olaparib.
Pembrolizumab boosts the power of the immune system to find and kill cancer cells; its use for breast cancer is investigational. Olaparib is used to treat TNBC; its use with pembrolizumab is investigational. Olaparib is taken orally (by mouth) and pembrolizumab is given intravenously (by vein).